Recent data from the NeoCol trial evaluates whether neoadjuvant chemotherapy colon cancer protocols improve patient outcomes compared to standard upfront surgery. Locally advanced colon cancer carries a high risk of recurrence. Consequently, researchers investigated if preoperative systemic therapy could reduce this risk. While neoadjuvant treatment is standard for rectal and gastric malignancies, its application in colon cancer remains a subject of clinical debate.

Outcomes of the NeoCol Trial

This randomized, phase III trial enrolled 250 patients across Denmark, Norway, and Sweden. The investigators randomized participants to either upfront surgery or three cycles of neoadjuvant capecitabine and oxaliplatin (CAPOX). At the 3-year follow-up, disease-free survival (DFS) was 87% in the surgery-first group and 83% in the neoadjuvant group. Because the difference was not statistically significant, the trial concluded as a negative study for survival improvement.

Downstaging and Surgical Safety

Despite the lack of survival advantage, neoadjuvant chemotherapy colon cancer strategies demonstrated clear clinical utility. Specifically, preoperative therapy successfully achieved tumor downstaging in many patients. Furthermore, it reduced the proportion of patients who eventually required intensive postoperative adjuvant chemotherapy (59% vs 73%). The study also confirmed that neoadjuvant treatment is safe and feasible, as it did not increase postoperative complications or negatively impact quality of life.

Impact of Mismatch Repair Status

The trial included an exploratory analysis regarding mismatch repair (MMR) status. Interestingly, DFS estimates were higher for patients with MMR-deficient (dMMR) tumors when they underwent upfront surgery. This finding suggests that standard chemotherapy may be less effective for dMMR subtypes in the neoadjuvant setting. Therefore, clinicians must consider molecular profiling when personalizing management strategies for locally advanced disease.

Frequently Asked Questions

Does neoadjuvant chemotherapy replace surgery for colon cancer?

No, neoadjuvant chemotherapy is used before surgery to shrink the tumor. However, surgical resection remains the definitive curative treatment for locally advanced colon cancer.

What were the main benefits of the neoadjuvant approach in the NeoCol trial?

Although it did not improve survival rates, neoadjuvant chemotherapy was safe and helped downstage tumors. Additionally, it reduced the need for chemotherapy after surgery for many patients.

Should MMR status influence the choice of neoadjuvant therapy?

Yes, the NeoCol trial suggested that patients with dMMR tumors might have better outcomes with upfront surgery. This highlights the importance of biomarker testing before starting treatment.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always consult a qualified healthcare professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Jensen LH et al. Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical Trial. JAMA Surg. 2026 Mar 04. doi: 10.1001/jamasurg.2026.0085. PMID: 41779406.


2. Morton D, et al. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial (FOxTROT). J Clin Oncol. 2023;41(8):1541-1552.


3. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer, Version 4.2025.